|
| Graduate |
University of Miyazaki, Miyazaki Medical College, Japan |
|
2002 |
PhD |
|
|
Appointment Type |
Department |
Division |
Rank |
| Primary |
Genetics Research Div |
Genetics Research Div |
Professor |
| Center |
Comprehensive Cancer Center |
Comprehensive Cancer Center |
Professor |
| Center |
Ctr for Clinical & Translational Sci |
Ctr for Clinical & Translational Sci |
Professor |
|
| Cancer Biology |
| Cellular and Molecular Biology Program |
| Genetics and Genomic Sciences |
|
| Publication |
PUBMEDID |
1. Wang C, Leavenworth J, Zhang C, Liu Z, Yuan KY, Wang Y, Zhang G, Wang S, Cui X, Zhang Y, Bae S, Zhou J, Wang L, and Liu R*. Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer. Oncogene 2022 May;41(19):2778-2785. doi: 10.1038/s41388-022-02272-3. PMID: 35361883
2. Gao S, Zhang C, Wang S, Zhao Z, Xu Z, Yi B, Jiao K, Naik G A., Wei S, Rais-Bahrami S, Bae S, Yang WH, Sonpavde G, Liu R* and Wang L*. TUBB4A interacts with MYH9 and activates NF-κB signaling, facilitating nucleus protection and metastatic process in prostate cancer. Nature Communications 2022 May 19;13(1):2792. doi: 10.1038/s41467-022-30409-1
3. Zhang Y, Xu Z, Wen W, Zhang CX, Wei S, Bae S, Rais-Bahrami S, Liu R*, and Wang L*. The microRNA-3622 family at the 8p21 locus exerts oncogenic effects by regulating the p53-downstream gene network in prostate cancer progression Oncogene. 2022 May 2. doi: 10.1038/s41388-022-02289-8. PMID: 35501464. Online ahead of print.
4. Cui X, Zhang C, Xu Z, Wang S, Li X, Stringer-Reasor E, Bea S, Zeng L, Zhao D, Liu R*, Qi LS*, Wang L*. Dual CRISPR Interference and Activation for Targeted Reactivation of X-linked Endogenous FOXP3 in Human Breast Cancer Cells. Molecular Cancer, 2022 Feb 7;21(1):38. doi: 10.1186/s12943-021-01472-x. PMID: 35130925.
5. Yi B, Wand S, Wang X, Liu Z, Zhang C, Li M, Gao S, Wei S, Bae S, Stringer-Reasor E, Wang L, Liu R*. CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer. Oncogene 2022 Jan;41(2):268-279. doi: 10.1038/s41388-021-02089-6. Epub 2021 Nov 2.PMID: 34728806.
6. Si Y, Zhang Y, Guan JS, Ngo HG, Totoro A, Singh AP, Chen K, Xu Y, Yang ES, Zhou L, Liu R, Liu XM. Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers. Vaccines (Basel). 2021 August 10; 9(8):882. doi: 10.3390/vaccines9080882. PMID: 34452008
7. Wu Y, Yang D, Liu R, Wang L, Chen GY. Selective Response to Bacterial Infection by Regulating Siglec-E Expression. iScience. 2020; 23(9):101473. doi: 10.1016/ j.isci.2020.101473. PMID: 32889432
8. Wang M, Zhang G, Zhang Y, Cui X, Wang S, Gao S, Wang Y, Liu Y, Bae JH, Yang WH, Qi LS, Wang L, Liu R*. Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis through Integrin-AKT Signaling Pathway in Lung Cancer. Mol Cancer Res, 2020; 18(7): 943-954. doi: 10.1158/1541-7786.MCR-19-1033. PMID: 32205365.
9. Liu W, Zhang Y, Wei S, Bae S, Yang WH, Smith GJ, Mohler JL, Fontham ETH, Bensen JT, Sonpavde GP, Chen GY, Liu R*, Wang L*. A CD24-p53 axis contributes to African American prostate cancer disparities. Prostate. 2020; 80(8): 609-618. doi: 10.1002/ pros.23973. PMID: 32168400.
10. Wang Y, Li X, Liu W, Li B, Chen D, Hu F, Wang L, Liu X, Cui R, and Liu R*. MicroRNA- 1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer. Oncogene, 2019; 38(24):4820- 4834. doi: 10.1038/s41388-019-0760-3.
11. Wu L, Yi B, Yao D, He Y, Naik GN, Bea S, Liu X, Yang WH, Sonpavde G, Liu R*, and Wang L*. Losses of Foxp3 and Tsc1 Accelerate Prostate Cancer Progression through a Synergistic Transcriptional and Post-translational Regulation of c-MYC. Cancer Research. 2019; 79(7): 1413–1425. doi: 10.1158/0008-5472.CAN-18-2049.
12. Wang CM, William H. Yang, Liu R, Wang L, Yang WH. FOXP3 activates SUMO- conjugating UBC9 gene in MCF7 breast cancer cells. Int J Mol Sci. 2018; 19(7). pii: E2036. doi: 10.3390/ijms19072036.
13. Ou J, Si Y, Goh K, Yasui N, Guo Y, Song J, Wang L, Jaskula-Sztul R, Fan J, Zhou L, Liu R, Liu X1. Bioprocess development of antibody-drug conjugate production for cancer treatment. PLoS One 2018; 13(10): e0206246. doi: 10.1371/ journal.pone. 0206246.
14. Luo Y, Li B, Zhang G, He Y, Bae JH, Hu F, Cui R, Liu R, Wang Z, Wang L. Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer. 2018; 9(6):1096- 1105. doi: 10.7150/jca.23909. eCollection 2018.PMID: 29581789
15. Gao S, Wang Y, Wang M, Li Z, Zhao Z, Chen D, Wu R, Yuan Z, Wang XR, Cui R, Wang L, Ouyang L and Liu R* MicroRNA-155, induced by FOXP3 though a transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget. 2017 Jun 20;8(25): 41451-41464.
16. Wang CM, Wang RX, Liu R, Yang WH. Jun Dimerization Protein 2 Activates Mc2r Transcriptional Activity: Role of Phosphorylation and SUMOylation. Int J Mol Sci. 2017 January 31;18(2).
17. Zhang G, Zhang W, Li B, Stringer-Reasor E, Chu C, Sun L, Bae S, Chen D, Wei S, Jiao K, Yang WH, Cui R, Liu R*, Wang L. MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer. Breast Cancer Res. 2017; 19(1):73.
18. Zhang Y, Li B, Zhang X, Sonpavde GP, Jiao K, Zhang A, Zhang G, Sun M, Chu C, Li F, Wang L, Cui R, Liu R*. CD24 Is a Genetic Modifier for Risk and Progression of Prostate Cancer. Mol Carcinog 2017; 56(2):641-650. doi: 10.1002/mc.22522. PMID: 27377469
19. Liu W, Liu R, Wang L. Androgen metabolism genes in prostate cancer health disparities. Cancer Health Disparities. 2017;1:e1-e6. doi: 10.9777/rr.2017.10003. Epub 2017 November 18.PMID: 30756097
20. Zhang W, Yi B, Wang C, Chen D, Bae S, Wei S, Guo RJ, Lu C, Nguyen LLH, Yang WH, Lillard JW, Zhang X, Wang L, Liu R*. Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells. Clin Cancer Res. 2016; 22(10):2545- 54. doi: 10.1158/1078-0432.CCR-15-1927.
21. Zhang G, Wang C, Sun M, Li J, Wang B, Jin C, Hua P, Song G, Zhang Y, Nguyen LL, Cui R, Liu R, Wang L, Zhang X. Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells. Oncotarget. 2016 March 3. doi: 10.18632/oncotarget.7898.
22. Daubenspeck JM, Liu R, Dybvig K. Rhamnose Links Moonlighting Proteins to Membrane Phospholipid in Mycoplasmas. PLOS ONE. DOI:10.1371/ journal.pone. 0162505 September 7, 2016, 1 – 11.
23. Meredith LJ, Wang CM, Nascimento L, Liu R, Wang L, Yang WH. The Key Regulator for Language and Speech Development, FOXP2, is a Novel Substrate for SUMOylation. J Cell Biochem. 2016 117:426–438.
24. Liu R*, Liu C, Chen D, Yang WH, Liu X, Liu CG, Dugas CM, Tang F, Zheng P, Liu Y, Wang L*. FOXP3 controls an miR-146/NFκB negative feedback loop that inhibits apoptosis in breast cancer cells. Cancer Res. 2015 April 15; 75(8):1703-13
25. Liu R*, Yi B, Wei S, Yang WH, Hart KM, Chauhan P, Zhang W, Mao X, Liu X, Liu CG, and Wang L*. FOXP3-miRNA146-NF-κB axis and therapy for precancerous lesion in prostate. Cancer Res. 2015 April 15;75(8):1714-24
26. Etikala EM, Liu R, Wang L. FOXP3-microRNA-146-NF-κB as oncotarget. Oncoscience,
2015 Aug 26;2(10):839-40.
27. Parker DJ, Iyer A, Shah SK, Moran A, Hjelmeland AB, Basu MK, Liu R Mitra K. A novel mitochondrial pool of Cyclin E, regulated by Drp1, is linked to cell density dependent cell proliferation. J Cell Sci. 2015 Nov 15; 128 (22):4171-82.
28. Etikala DM, Liu R, Wang L. FOXP3-microRNA-146-NF-κB as oncotarget. Oncoscience. 2015 Aug 26;2(10):839-40. doi: 10.18632/oncoscience.220. eCollection 2015.
PMID: 26682271
29. Wang L*, Liu R*(* first co-author), Ye P, Wong C, Chen GY, Zhou P, Sakabe K, Zheng X, Wu W, Zhang P, Jiang T, Bassetti MF, Jube S, Sun Y, Zhang Y, Zheng P, Liu Y. Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation. Nature Communications, 2015 Jan 20; 6:5909.
30. Ye P, Liu Y, Chen C, Tang F, Wu Q, Wang X, Liu CG, Liu X, Liu R, Liu Y, Zheng P. An mTORC1-Mdm2-Drosha Axis for miRNA Biogenesis in Response to Glucose- and Amino Acid-Deprivation. Mol Cell. 2015 Feb 19;57(4):708-20.
31. Wang CM, Liu R, Wang L, Nascimento L, Brennan VC, Yang WH. SUMOylation of FOXM1B alters its transcriptional activity on regulation of MiR-200 family and JNK1 in MCF7 human breast cancer cells. Int J Mol Sci. 2014;15(6):10233-51.
32. Wang CM, Liu R, Wang L, Yang WH. Acidic residue Glu199 increases SUMOylation level of nuclear hormone receptor NR5A1. Int J Mol Sci. 2013; 14(11): 22331-45.
33. Liu R, Li S, Yang WH, Wang L. IPEX Syndrome, FOXP3 and Cancer. J Syndr. 2013 Jun;1(1). pii: 7.
34. Liu R, Kain M, Wang L. Inactivation of X-linked tumor suppressor genes in human cancer. Future Oncology. 2012; 8 (4): 463-81.
35. Wang L, Liu R, Li D, Lin S, Fang X, Backer G, Kain M, Rammoham K, Zheng P, Liu Y. A hypermorphic SP1-binding CD24 variant associated with risk and progression of multiple sclerosis. Am J Transl Res. 2012; 4(3): 347-56.
36. Li W, Wang L, Katoh H, Liu R, Zheng P, Liu Y. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res. 2011; 71 (6): 2162-71.
37. Katoh H, Qin ZS, Liu R, Wang L, Li W, Li X, Wu L, Du Z, Lyons R, Liu CG, Liu X, Dou Y, Zheng P, Liu Y. FOXP3 Orchestrates H4K16 Acetylation and H3K4 Tri-Methylation for Gene Activation through Recruiting MOF and Displacing H3K4 Demethylase. Mol Cell. 2011; 44(5): 770-84.
38. Wang L, Liu R, Ribick M, Zheng P, Liu Y. FOXP3 as an X-linked tumor suppressor.
Discov Med. 2010; 10(53): 322-8.
39. Wang L*, Liu R*(* first co-author), Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y, Zheng P. Somatic Single-hits Inactivate the X-linked Tumor Suppressor FOXP3 in the Prostate. Cancer Cell, 2009; 16 (4): 336-46.
40. Liu R, Wang L, Chen C, Katoh H, Chen C, Zheng P, Liu Y. FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/4 association to the locus. Cancer Res. 2009; 69 (6): 2252-9.
41. Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Liu Y, Zheng P. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med., 2008; 205(10): 2397-408.
42. Liu R, Wang L, Chen C, Liu Y, Zhou P, Wang Y, Wang X, Turnbull J, Minassian BA, Liu Y, Zheng P. Laforin negatively regulates cell cycle progression through GSK-3b dependent mechanisms. Mol Cell Biol. 2008; 28 (23): 7236-44.
43. Wang L, Lin S, Rammohan KW, Liu Z, Liu JQ, Liu R, Guinther N, Lima J, Zhou Q, Wang T, Zheng X, Birmingham DJ, Rovin BH, Hebert LA, Wu Y, Lynn DJ, Cooke G, Yu CY, Zheng P, Liu Y. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genetics, 2007; 3(4): 508-17.
44. Saitoh Y, Liu R, Ueno H, Mizuta M, Nakazato M. Oral pioglitazone administration increases food intake through ghrelin-independent pathway in Zucker fatty rat. Diabetes Res Clin Pract. 2007; 77(3): 351-6.
45. Zuo T*, Liu R*(* first co-author) Zhang H, Chang X, Liu Y, Wang L, Zheng P and Liu Y FOXP3 is a novel transcription repressor for the breast cancer oncogene SKP2.
J Clin Invest, 2007; 117(12): 3765-73.
46. Liu RH, Mizuta M, Matsukura S. The expression and functional role of nicotinic acetylcholine receptors in rat adipocytes. J Pharmacol Exp Ther. 2004; 310(1): 52-8.
47. Liu RH, Mizuta M, Matsukura S. Long-term oral nicotine administration reduces insulin resistance in obese rats. Eur J Pharmacol. 2003; 458(1-2): 227-34.
48. Liu RH, Mizuta M, Kurose T, Matsukura S. Early events involved in the development of insulin resistance in Zucker fatty rat. Int J Obes Relat Metab Disord. 2002; 26(3):318- 26.
49. Liu RH*, Kurose T, Matsukura S. Oral nicotine administration decreases tumor necrosis factor-alpha expression in fat tissues in obese rats. Metabolism. 2001; 50(1):79-85.
|
|
|
|
